The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) ROE %: 0.00% (As of . 20)


DHA:IBNSINA The IBN SINA Pharmaceutical Industry PLC DHA:IBNSINA
20 GF Score
Price BDT318.20
View Full Analysis

What is The IBN SINA Pharmaceutical Industry ROE %?

The IBN SINA Pharmaceutical Industry DHA:IBNSINA +0.47% 20 ROE % is 0.00% as of . 20. GuruFocus rates DHA:IBNSINA with a GF Score™ of 20/100. Among 936 Drug Manufacturers companies, The IBN SINA Pharmaceutical Industry ranks worse than 106837.5% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. The IBN SINA Pharmaceutical Industry's annualized net income for the quarter that ended in . 20 was BDT Mil. The IBN SINA Pharmaceutical Industry's average Total Stockholders Equity over the quarter that ended in . 20 was BDT Mil. Therefore, The IBN SINA Pharmaceutical Industry's annualized ROE % for the quarter that ended in . 20 was %.

The historical rank and industry rank for The IBN SINA Pharmaceutical Industry's ROE % or its related term are showing as below:

DHA:IBNSINA's ROE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 5.865
* Ranked among companies with meaningful ROE % only.

The IBN SINA Pharmaceutical Industry  (DHA:IBNSINA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=( / )*( / )*( / )
=Net Margin %*Asset Turnover*Equity Multiplier
= %**
=ROA %*Equity Multiplier
= %*
= %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: . 20 )
=Net Income/Total Stockholders Equity
=/
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= ( / ) * ( / ) * ( / ) * ( / ) * ( / )
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= * * % * *
= %

Note: The net income data used here is one times the annual (. 20) net income data. The Revenue data used here is one times the annual (. 20) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


The IBN SINA Pharmaceutical Industry ROE % Related Terms


The IBN SINA Pharmaceutical Industry ROE % Historical Data

* Premium members only.

The historical data trend for The IBN SINA Pharmaceutical Industry's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The IBN SINA Pharmaceutical Industry ROE % Chart

The IBN SINA Pharmaceutical Industry Annual Data
Trend
ROE %

The IBN SINA Pharmaceutical Industry Semi-Annual Data
ROE %

DHA:IBNSINA vs IMNPQ: ROE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, The IBN SINA Pharmaceutical Industry's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


The IBN SINA Pharmaceutical Industry ROE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, The IBN SINA Pharmaceutical Industry's ROE % distribution charts can be found below:

* The bar in red indicates where The IBN SINA Pharmaceutical Industry's ROE % falls into.


DHA:IBNSINA
20GF Score
The IBN SINA Pharmaceutical Industry PLC DHA:IBNSINA
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

The IBN SINA Pharmaceutical Industry ROE % Calculation

The IBN SINA Pharmaceutical Industry's annualized ROE % for the fiscal year that ended in . 20 is calculated as

ROE %=Net Income (A: . 20 )/( (Total Stockholders Equity (A: . 20 )+Total Stockholders Equity (A: . 20 ))/ count )
=/( (+)/ )
=/
= %

The IBN SINA Pharmaceutical Industry's annualized ROE % for the quarter that ended in . 20 is calculated as

ROE %=Net Income (Q: . 20 )/( (Total Stockholders Equity (Q: . 20 )+Total Stockholders Equity (Q: . 20 ))/ count )
=/( (+)/ )
=/
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is one times the annual (. 20) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a ROE % of 0.00% as of . 20. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. According to the industry distribution chart, The IBN SINA Pharmaceutical Industry ranks #999999 out of 936 companies in the Drug Manufacturers industry.
Is The IBN SINA Pharmaceutical Industry's ROE % too high?
The IBN SINA Pharmaceutical Industry's current ROE % is 0.00%. Based on the distribution chart, The IBN SINA Pharmaceutical Industry ranks #999999 out of 936 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, The IBN SINA Pharmaceutical Industry has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does The IBN SINA Pharmaceutical Industry's ROE % compare to IMNPQ?
According to the Drug Manufacturers industry distribution chart, The IBN SINA Pharmaceutical Industry ranks #999999 out of 936 companies for ROE %. This places The IBN SINA Pharmaceutical Industry in the lower half of its industry. The industry median ROE % is 5.87. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 5.87, based on 936 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on The IBN SINA Pharmaceutical Industry and its competitors. For the Drug Manufacturers industry, the median ROE % is 5.87 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The IBN SINA Pharmaceutical Industry's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The IBN SINA Pharmaceutical Industry stock overvalued right now?
The IBN SINA Pharmaceutical Industry (DHA:IBNSINA) has a current ROE % of 0.00%. The current ROE % is 0.00%. The IBN SINA Pharmaceutical Industry's overall GF Score™ is 20/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For The IBN SINA Pharmaceutical Industry (DHA:IBNSINA), the current ROE % is 0.00% as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The IBN SINA Pharmaceutical Industry Business Description

Address Mirpur Road, Tanin Center, 3 Asad Gate, Mohammadpur, Dhaka, BGD, 1207
The IBN SINA Pharmaceutical Industry PLC is engaged in the production and marketing of pharmaceutical drugs and natural medicines in both the local and international market.
20GF Score

Get the complete analysis for DHA:IBNSINA

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT318.20
Price